NLS Agreement

InDex Pharmaceuticals has announced that a license agreement has been signed with Viatris Pharmaceutical Japan to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. “We are excited to start our collaboration with Viatris Japan with the common goal to register and commercialize cobitolimod for the Japanese market. Viatris Japan shares our […]

The two companies have announced a research and development collaboration to discover and develop gene editing therapies against a select set of therapeutic targets. With a focus on advancing base editing capabilities, Novo Nordisk will leverage Life Edit’s suite of gene editing technologies to precisely edit the genome with the aim of developing life-changing therapies […]

IRLAB Therapeutics has announced the signing of an agreement, with the McQuade Center for Strategic Research and Development (MSRD), a member of the global Otsuka family of pharmaceutical companies. Under the agreement MSRD will evaluate the neuropsychiatric compounds IRL757 and IRL942 under exclusivity. MSRD, which identifies and supports early-stage opportunities that can change the landscape […]

Umeå based HiloProbe has entered a partnership with the major international company Biocartis Group. This is a strategically important step for HiloProbe in their aim to reach out globally with its colorectal cancer test-product, ColoNode, they state. “We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus […]

Alligator Bioscience has announced that Orion Corporation has selected bispecific lead antibodies and is exercising its option to develop these molecules under the existing research collaboration and license agreement between the two companies. Alligator will continue to generate additional data in order for Orion to select the final development candidate over the coming months. Upon […]

The agreement focuses on activators of KCNQ2, an ion channel that has been clinically validated as a target for the treatment of epilepsy. Clinical findings suggest that activation of KCNQ2 channels may provide treatment options for other types of neurological disorders including rare forms of epilepsy. Read more: Lundbeck and Alloy Therapeutics collaborate Under the […]